Abstract
Continuous levodopa replacement still is the most efficacious treatment for patients with Parkinson's disease. Unfortunately, the neutral aromatic amino acids contained in dietary proteins may compete with this drug for intestinal absorption and transport across the blood-brain barrier, thus limiting its efficacy and being responsible for the occurrence of motor fluctuations. Current guidelines recommend low-protein dietary regimens with protein redistribution, as shifting protein intake to the evening has proved to ameliorate the response to levodopa. However, adherence to this dietary regimen does not seem to be satisfactory and response is variable. Recent studies have shown that low-protein products designed for chronic renal failure patients are safe, tasty, well-tolerated and useful in improving both adherence to low-protein dietary regimens and levodopa-related motor fluctuations. However, there still is the need to define the selection criteria for the patients who may benefit the most from adherence to this regimen.
| Original language | English |
|---|---|
| Pages (from-to) | 29-32 |
| Number of pages | 4 |
| Journal | Nutritional Neuroscience |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 1 2010 |
Fingerprint
Keywords
- Diet
- Dietary protein
- Levodopa
- Motor fluctuations
- Nutrition
- Parkinson's disease
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Nutrition and Dietetics
- Neuroscience(all)
Cite this
Controlled-protein dietary regimens for Parkinson's disease. / Cereda, Emanuele; Barichella, Michela; Pezzoli, Gianni.
In: Nutritional Neuroscience, Vol. 13, No. 1, 01.02.2010, p. 29-32.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Controlled-protein dietary regimens for Parkinson's disease
AU - Cereda, Emanuele
AU - Barichella, Michela
AU - Pezzoli, Gianni
PY - 2010/2/1
Y1 - 2010/2/1
N2 - Continuous levodopa replacement still is the most efficacious treatment for patients with Parkinson's disease. Unfortunately, the neutral aromatic amino acids contained in dietary proteins may compete with this drug for intestinal absorption and transport across the blood-brain barrier, thus limiting its efficacy and being responsible for the occurrence of motor fluctuations. Current guidelines recommend low-protein dietary regimens with protein redistribution, as shifting protein intake to the evening has proved to ameliorate the response to levodopa. However, adherence to this dietary regimen does not seem to be satisfactory and response is variable. Recent studies have shown that low-protein products designed for chronic renal failure patients are safe, tasty, well-tolerated and useful in improving both adherence to low-protein dietary regimens and levodopa-related motor fluctuations. However, there still is the need to define the selection criteria for the patients who may benefit the most from adherence to this regimen.
AB - Continuous levodopa replacement still is the most efficacious treatment for patients with Parkinson's disease. Unfortunately, the neutral aromatic amino acids contained in dietary proteins may compete with this drug for intestinal absorption and transport across the blood-brain barrier, thus limiting its efficacy and being responsible for the occurrence of motor fluctuations. Current guidelines recommend low-protein dietary regimens with protein redistribution, as shifting protein intake to the evening has proved to ameliorate the response to levodopa. However, adherence to this dietary regimen does not seem to be satisfactory and response is variable. Recent studies have shown that low-protein products designed for chronic renal failure patients are safe, tasty, well-tolerated and useful in improving both adherence to low-protein dietary regimens and levodopa-related motor fluctuations. However, there still is the need to define the selection criteria for the patients who may benefit the most from adherence to this regimen.
KW - Diet
KW - Dietary protein
KW - Levodopa
KW - Motor fluctuations
KW - Nutrition
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=76749132089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76749132089&partnerID=8YFLogxK
U2 - 10.1179/147683010X12611460763760
DO - 10.1179/147683010X12611460763760
M3 - Article
C2 - 20132652
AN - SCOPUS:76749132089
VL - 13
SP - 29
EP - 32
JO - Nutritional Neuroscience
JF - Nutritional Neuroscience
SN - 1028-415X
IS - 1
ER -